Matches in DBpedia 2016-04 for { ?s ?p "Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug currently that was under development by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.[1] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%). "@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Pardoprunox comment "Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug currently that was under development by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.[1] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%). ".
- Q7136602 comment "Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug currently that was under development by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.[1] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%). ".